| 张晨晨,孙晓斐,丛培玲,魏子秀.瑞舒伐他汀对双腔起搏器患者心房高频事件的影响[J].济宁医学院学报,2014,(2):106-108 |
| 瑞舒伐他汀对双腔起搏器患者心房高频事件的影响 |
| Effect of rosuvastatin on reducing paroxysmal atrial fibrillation after dual-chamber-pacemaker implantation |
| 投稿时间：2014-02-15 |
| DOI：10.3969/j.issn.1000-9760.2014.02.010 |
| 中文关键词: 瑞舒伐他汀;双腔起搏器;C反应蛋白 |
| 英文关键词: Atrial fibrillation;Sick sinus syndrome;Dual·chamber pacing;rosuvastation |
| 基金项目: |
| 作者 | 单位 | | 张晨晨 | 济南大学山东省医学科学院医学与生命科学学院, 山东济南 250200
济宁医学院附属济宁市第一人民医院, 山东济宁 272011 | | 孙晓斐 | 济宁医学院附属济宁市第一人民医院, 山东济宁 272011 | | 丛培玲 | 济宁医学院附属济宁市第一人民医院, 山东济宁 272011 | | 魏子秀 | 济宁医学院附属济宁市第一人民医院, 山东济宁 272011 |
|
| 摘要点击次数: 5065 |
| 全文下载次数: 1016 |
| 中文摘要: |
| 目的 观察瑞舒伐他汀对病态窦房结综合征(sick sinus syndrome,SSS)合并阵发性心房颤动(atrial fibrillation,PAF)双腔起搏器(dual chamber pacemaker,DDD)术后心房高频事件(atrial high-frequency events,AHREs)的影响。方法 选择具有DDD植入术指征的SSS合并PAF成功行DDD植入术患者65例,随机分为观察组(34例)、对照组(31例),两组术后均服用美托洛尔缓释片(23.75mg 早1次)、观察组加用瑞舒伐他汀(10mg, 晚1次)。随访观察12个月,比较观察组与对照组患者服药1a后心房、心室起搏特点、C反应蛋白(C-reactive protein, CRP)差异性及心房高频事件(包括发作次数、发作持续时间)发生情况。结果 治疗12个月后,观察组与对照组心房起搏、心室起搏比例无显著差异,而观察组CRP值较对照组显著降低,且差异具有统计学意义。比较两组起搏器程控时记录到的心房高频事件,观察组心房高频事件较对照组明显减少(P<0.05),差异具有统计学意义。结论 瑞舒伐他汀可以抑制病窦综合征伴阵发房颤患者双腔起搏术后心房重构、炎症反应,进而减少心房高频事件的发生。 |
| 英文摘要: |
| Objective To evaluate the effect of rosuvastatin on reducing paroxysmal atrial fibrillation after dual-chamber-pacemaker implantation in patients who sicked sinus syndrome(SSS)and paroxysmal atrial fibrillation.Methods Sixty-five patients with SSS who was suffering from PAF following dual-chamber-pacemaker implantation were randomly divided into the treatment group and the control group.On the basis of the treatment of original diseases,the control group were given metoprolol,while the treatment group were administrated with rosuvastatin,10mg served everyday,as well as metoprolol.After twelve months follow-up and observation,CRP,AP%,VP%,the PAF times and AF duration(AHREs)were observed.Results CRP,PAF times and AF persistence time(AHREs) recorded by the pacemaker.The effective power of AF treatment in the treatment group were lower than those in the control group(P<0.05),and in the treatment goup they were decreased significantly.Conclusion Rosuvastation can effectively inhibit the occurrence of PAF after dual-chamber-pacemaker implantation in patients with SSS who were suffered with PAF by inhibiting atrial remodeling and Inflammatory reaction. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
|
|
|
